HLA-B Allele Detection Kit for SCAR Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively assess and mitigate the risk of severe cutaneous adverse drug reactions (SCARs) induced by disease-modifying antirheumatic drugs like Sulfasalazine, Mesalazine, and Sulfapyridine, which can lead to severe conditions such as Stevens Johnson Syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms.
Innovation Solution
A method involving the detection of specific HLA-B alleles (HLA-B*1502, HLA-B*3802, and combinations thereof) to assess the risk of developing SCARs, using a detection kit with oligonucleotide primers and probes to identify these alleles in patient samples, thereby indicating an increased risk of adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If disease-modifying antirheumatic drugs are used to treat inflammatory diseases, then anti-inflammatory and immunosuppressive effects are achieved, but the risk of severe cutaneous adverse drug reactions increases
Solution Approach 1:
The patent performs HLA-B allele detection before initiating disease-modifying antirheumatic drug treatment to identify patients at high risk for severe cutaneous adverse reactions. This preliminary genetic screening allows clinicians to prevent adverse events by avoiding contraindicated drugs or implementing enhanced monitoring protocols for at-risk individuals, thereby resolving the contradiction between treatment effectiveness and safety risk.
2Measurement precision
If HLA typing is performed to assess adverse reaction risk, then prediction accuracy improves, but detection complexity increases
Solution Approach 1:
The patent extracts and detects only the specific HLA-B alleles (HLA-B*1502, HLA-B*3802, HLA-B*1301, HLA-B*3901) that are scientifically established to be associated with severe cutaneous adverse reactions to disease-modifying antirheumatic drugs. By focusing on this limited set of high-risk alleles rather than performing comprehensive HLA typing of all 900+ HLA-B subtypes, the method achieves high prediction accuracy while significantly reducing detection system complexity and clinical implementation burden.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly increases the ability to predict and reduce the incidence of severe cutaneous adverse drug reactions by identifying at-risk individuals, allowing for targeted prevention and treatment strategies.
Implementation Method 1
A method involving the detection of specific HLA-B alleles (HLA-B*1502, HLA-B*3802, and combinations thereof) to assess the risk of developing SCARs, using a detection kit with oligonucleotide primers and probes to identify these alleles in patient samples
Data Source
AI summary
A method for assessing the risk of severe cutaneous adverse drug reactions (SCARs) induced by disease-modifying antirheumatic drugs is provided, wherein the severe cutaneous adverse drug reactions comprises but not being limited to: Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug rash with eosinophilia and systemic symptoms (DRESS). Also provided is a detection kit for assessing the risk of developing cutaneous adverse drug reactions in a subject, said kit comprising a reagent for determining specific HLA alleles and a use of the detection kit in assessing the risk of developing cutaneous adverse drug reactions in a subject.